gentamicin has been researched along with Hearing Loss in 138 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ototoxic hearing loss was induced by intravenous administration of cisplatin, gentamicin, and furosemide." | 8.12 | Intratympanic Administration of Dieckol Prevents Ototoxic Hearing Loss. ( Li, H; Oh, SH; Shin, HC; Suh, MW, 2022) |
| "Gentamicin (GM) is a commonly used antibiotic, and ototoxicity is one of its side effects." | 8.02 | Puerarin alleviates the ototoxicity of gentamicin by inhibiting the mitochondria‑dependent apoptosis pathway. ( Li, G; Niu, P; Pan, C; Sun, J; Sun, Y; Tang, X; Wang, S, 2021) |
| "Artemisinin (ART) is a natural anti-malarial sesquiterpene lactone which has the ability to treat and activate the CLRN1 pathway to play a pivotal role in hearing loss and hair cell function." | 7.96 | Artemisinin Loaded mPEG-PCL Nanoparticle Based Photosensitive Gelatin Methacrylate Hydrogels for the Treatment of Gentamicin Induced Hearing Loss. ( Li, X; Tang, L; Wang, Y; Webster, TJ; Xu, F; Xu, Y; Zhang, F, 2020) |
| "Gentamicin is a widely used antibiotic for the treatment of gram-negative bacterial infections; however, its use often results in significant and permanent hearing loss." | 7.91 | Pasireotide protects mammalian cochlear hair cells from gentamicin ototoxicity by activating the PI3K-Akt pathway. ( Bodmer, D; Horvath, L; Kucharava, K; Petkovic, V; Sekulic-Jablanovic, M, 2019) |
| " The majority of NICU admissions receive potentially ototoxic aminoglycoside therapy, such as gentamicin, for presumed sepsis." | 7.81 | Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure. ( Cross, CP; Garinis, AC; Liao, S; Srikanth, P; Steyger, PS; Urdang, ZD, 2015) |
| "To determine the safety of gentamicin when used in a community setting to treat neonatal sepsis." | 7.79 | Risk of hearing loss in children exposed to gentamicin for the treatment of sepsis in young infancy: a community based cohort study in Pakistan. ( Ali, SA; Azam, I; Iftikhar, U; Saleem, S; Tikmani, SS; Zaidi, AK, 2013) |
| " Reactive oxygen species contribute to the formation of several types of cochlear injuries, including age-related hearing loss and gentamicin ototoxicity." | 7.77 | Protective role of Nrf2 in age-related hearing loss and gentamicin ototoxicity. ( Hara, A; Hoshino, T; Ishii, T; Nakayama, M; Nishimura, B; Shimizu, R; Tabuchi, K; Tanaka, S; Warabi, E; Yamamoto, M; Yanagawa, T, 2011) |
| "To compare proportions of the combined outcome of vertigo control and hearing preservation between intratympanic gentamicin injections and endolymphatic sac shunt surgery for intractable vertigo in Ménière's disease patients." | 7.76 | Outcomes of endolymphatic shunt surgery for Ménière's disease: comparison with intratympanic gentamicin on vertigo control and hearing loss. ( Berliner, K; Chung, J; Derebery, MJ; Fisher, LM; Green, K, 2010) |
| "To study the therapeutic effect of insulin-like growth factor-1 (IGF-1) injection into the inner ears through a scala tympani fenestration on sensorineural deafness in a guinea pig model of gentamicin-induced hearing loss." | 7.74 | [Therapeutic effect of insulin-like growth factor-1 injection into the inner ears through scala tympani fenestration on gentamicin-induced hearing loss in guinea pigs]. ( Chen, H; Guo, MH; Li, YH, 2008) |
| "To study the protective effect of local gene therapy with adeno-associated virus (AAV)-mediated neurotrophin-3 (NT-3) on the function and morphology of the cochlea of guinea pigs with gentamicin-induced hearing loss." | 7.74 | [Protective effect of adeno-associated virus-mediated neurotrophin-3 on the cochlea of guinea pigs with gentamicin-induced hearing loss]. ( Li, SL; Liu, H; Wang, XX; Yan, LY; Yao, XB; Zhu, HL, 2007) |
| "To look for factors relating to the vertigo control and hearing changes after intratympanic injections of gentamicin (GM)." | 7.73 | Factors relating to the vertigo control and hearing changes following intratympanic gentamicin for intractable Ménière's disease. ( Fukushima, M; Horii, A; Kitahara, T; Kizawa, K; Kubo, T; Masumura, C; Mitani, K; Nakagawa, A; Nishiike, S; Nishimura, M; Saika, T; Sasaki, T; Uno, A, 2006) |
| "To determine whether patients with vestibulotoxic reactions to gentamicin have hearing thresholds worse than predicted by distributions of better-ear hearing thresholds in people of the same age and sex in the general population, and, if so, to measure the severity and audiometric pattern of that hearing loss." | 7.73 | Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. ( Black, FO; Dobie, RA; Pezsnecker, SC; Stallings, VL, 2006) |
| "To determine the incidence, extent, and time course of hearing loss following instillation of intratympanic gentamicin using a predetermined fixed protocol for incapacitating unilateral Meniere's disease and to determine whether such loss is associated with any identifiable risk factors." | 7.71 | Hearing loss following intratympanic instillation of gentamicin for the treatment of unilateral Meniere's disease. ( Al-Abidi, A; Chen, JM; Kaplan, DM; Nedzelski, JM; Shipp, DB, 2002) |
| "Intratympanic gentamicin is used to control dizziness of Ménière's disease, with a low rate of morbidity and a high success rate." | 7.70 | Low-dose intratympanic gentamicin treatment for dizziness in Ménière's disease. ( Longridge, NS; Mallinson, AI, 2000) |
| "Current drug candidates used to treat hearing loss commonly have low efficacy." | 5.48 | Novel SS-31 modified liposomes for improved protective efficacy of minocycline against drug-induced hearing loss. ( Gao, H; Hou, S; Kuang, X; Liu, H; Wang, Z; Yang, Y; Zhou, S, 2018) |
| "Gentamicin was used to induce neuronal hearing loss in mice, in the presence and absence of FA, followed by assessments of auditory brainstem response (ABR) and distortion product optoacoustic emissions (DPOAE) amplitude." | 5.46 | Ferulic acid promotes survival and differentiation of neural stem cells to prevent gentamicin-induced neuronal hearing loss. ( Cui, X; Gu, L; Li, X; Wei, W; Yang, J, 2017) |
| "Neuronal hearing loss has become a prevalent health problem." | 5.46 | Arctigenin protects against neuronal hearing loss by promoting neural stem cell survival and differentiation. ( Chen, M; Ding, Y; Huang, X; Wang, Q, 2017) |
| " Toxicity is dose related, but some patients may still develop hearing loss even under safe dosage." | 5.37 | Transient ischemia/hypoxia enhances gentamicin ototoxicity via caspase-dependent cell death pathway. ( Hsu, CJ; Kao, MC; Lai, CH; Lin, CD; Lin, CW; Lin, CY; Tang, CH; Tsai, MH; Wei, IH, 2011) |
| "Gentamicin application is an important therapeutic option for Ménière's disease." | 5.35 | Gentamicin increases nitric oxide production and induces hearing loss in guinea pigs. ( Brieger, J; Heinrich, UR; Helling, K; Li, H; Mann, WJ; Schmidtmann, I; Sifferath, M, 2008) |
| "Gentamicin is a widely used ototoxic agent." | 5.33 | Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss. ( Chen, S; Esteban-Cruciani, N; Fernandez-Zapico, ME; Kalinec, F; Kalinec, GM; Urrutia, R, 2005) |
| "Primary: to compare one-off administration of boric acid powder with courses of 1% acetic acid and ciprofloxacin eardrops in treating active chronic otitis media." | 5.16 | A randomised controlled trial of active chronic otitis media comparing courses of eardrops versus one-off topical treatments suitable for primary, secondary and tertiary healthcare settings. ( Loock, JW, 2012) |
| " We studied the possible protective effect of the antioxidant N-acetylcysteine (NAC) in gentamicin-induced hearing loss in hemodialysis patients." | 5.12 | Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. ( Abramsohn, R; Averbukh, Z; Efrati, S; Eviatar, E; Feldman, L; Gersch, E; Weissgarten, J; Yarovoy, I, 2007) |
| " Other common risk factors in this population were maternal infection during pregnancy, neonatal distress, low birth weight or prematurity, and gentamicin exposure." | 4.84 | Prevalence and etiology of hearing loss in rural Nicaraguan children. ( Greinwald, JH; Lai, J; Mojica, K; Morin, L; Saunders, JE; Vaz, S, 2007) |
| "Inclusion criteria to select articles for meta-analysis were clear description of gentamicin delivery technique, clearly reported vertigo control results, and report of hearing loss posttreatment." | 4.82 | Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. ( Anderson, JP; Chia, SH; Gamst, AC; Harris, JP, 2004) |
| "Children with hearing loss had lower birth weight for gestational age, more severe neonatal illness, with increased exposure to inotrope, steroid, gentamicin, vancomycin and furosemide, and more frequent physiological risk, elevated bilirubin and creatinine levels and acidosis, but no index child was found to have the m." | 4.31 | Cumulative risk factors contributing to hearing loss in preterm infants. ( Bitner-Glindzicz, M; Chant, K; Marlow, N, 2023) |
| " Ototoxic hearing loss was induced by intravenous administration of cisplatin, gentamicin, and furosemide." | 4.12 | Intratympanic Administration of Dieckol Prevents Ototoxic Hearing Loss. ( Li, H; Oh, SH; Shin, HC; Suh, MW, 2022) |
| "Ménière's disease (MD), characterized by episodic vertigo attacks and fluctuating progressive hearing loss, is treated by low-dose intratympanic gentamicin (ITG) injections." | 4.02 | Intratympanic gentamicin injection for refractory ménière's disease (MD) has potential effect in preventing contralateral MD occurrence. ( Dai, C; Song, Z; Wang, J; Wu, Y; Yu, J; Zhou, Y, 2021) |
| "Gentamicin (GM) is a commonly used antibiotic, and ototoxicity is one of its side effects." | 4.02 | Puerarin alleviates the ototoxicity of gentamicin by inhibiting the mitochondria‑dependent apoptosis pathway. ( Li, G; Niu, P; Pan, C; Sun, J; Sun, Y; Tang, X; Wang, S, 2021) |
| "Artemisinin (ART) is a natural anti-malarial sesquiterpene lactone which has the ability to treat and activate the CLRN1 pathway to play a pivotal role in hearing loss and hair cell function." | 3.96 | Artemisinin Loaded mPEG-PCL Nanoparticle Based Photosensitive Gelatin Methacrylate Hydrogels for the Treatment of Gentamicin Induced Hearing Loss. ( Li, X; Tang, L; Wang, Y; Webster, TJ; Xu, F; Xu, Y; Zhang, F, 2020) |
| "Photobiomodulation (PBM) has been suggested to have a therapeutic effect on irreversible hearing loss induced by aminoglycosides, including gentamicin (GM)." | 3.91 | Enhanced mitochondrial membrane potential and ATP synthesis by photobiomodulation increases viability of the auditory cell line after gentamicin-induced intrinsic apoptosis. ( Chang, SY; Choi, B; Chung, PS; Jung, JY; Kim, S; Lee, MY; Rhee, CK; Suh, MW, 2019) |
| "Gentamicin is a widely used antibiotic for the treatment of gram-negative bacterial infections; however, its use often results in significant and permanent hearing loss." | 3.91 | Pasireotide protects mammalian cochlear hair cells from gentamicin ototoxicity by activating the PI3K-Akt pathway. ( Bodmer, D; Horvath, L; Kucharava, K; Petkovic, V; Sekulic-Jablanovic, M, 2019) |
| "The aims of the present study are to investigate the variations in clinical features, including medical history, hearing function, vestibular function, and degree of endolymphatic hydrops (EH), in Meniere's disease (MD) patients with and without drop attacks (DAs), and to examine the efficacy of intratympanic gentamicin (ITG) treatment in alleviating DAs." | 3.91 | Clinical features and management of Meniere's disease patients with drop attacks. ( Dai, C; Li, X; Sha, Y; Wu, Q, 2019) |
| "Brainstem auditory evoked responses in dogs treated with aqueous solutions of marbofloxacin or gentamicin remained unchanged or improved after therapy of otitis media but were impaired in dogs treated with ticarcillin or tobramycin." | 3.88 | Brainstem auditory evoked responses in 37 dogs with otitis media before and after topical therapy. ( Paterson, S, 2018) |
| "Gentamicin-induced hearing loss in rats may be prevented by the concomitant use of vitamin A and N-acetylcysteine." | 3.83 | Prevention of gentamicin ototoxicity with N-acetylcysteine and vitamin A. ( Aladag, I; Guven, M; Songu, M, 2016) |
| "Extended interval dosing of gentamicin therapy in neonates does not increase the incidence of hearing loss." | 3.81 | Gentamicin extended interval regimen and ototoxicity in neonates. ( El-Barbary, MN; Ibrahim, AA; Ismail, RI, 2015) |
| " The majority of NICU admissions receive potentially ototoxic aminoglycoside therapy, such as gentamicin, for presumed sepsis." | 3.81 | Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure. ( Cross, CP; Garinis, AC; Liao, S; Srikanth, P; Steyger, PS; Urdang, ZD, 2015) |
| "Round window hyaluronic acid pledget technique used as a sustained delivery vehicle for intratympanic gentamicin treatment for Ménière's disease produces similar rates of vertigo control compared with other techniques but a greater risk of hearing loss." | 3.80 | Middle ear gentamicin-soaked pledgets in the treatment of Ménière's disease. ( Bottrill, ID; MacKeith, SA; Mawby, T; Whiteside, OJ, 2014) |
| "Oral supplementation with MitoQ attenuated gentamicin-induced cochlear damage and hearing loss in guinea pigs." | 3.80 | Mitochondria-targeted antioxidant MitoQ reduces gentamicin-induced ototoxicity. ( Antonelli, PJ; Le Prell, CG; Ojano-Dirain, CP, 2014) |
| "To explore the pattern of uptake of gentamicin into IHCs, as well as its possible contribution to hearing loss." | 3.80 | Dynamic distribution of ototoxic gentamicin entry into inner hair cells of mice. ( Hou, Z; Ji, F; Liu, K; Shi, C; Shi, L; Sun, Y; Wang, X; Xu, Y; Yang, S, 2014) |
| " Here, we report that quantitative changes in the number of IHC ribbon synapses and hearing loss occur in response to gentamicin treatment in mice." | 3.79 | Cochlear inner hair cell ribbon synapse is the primary target of ototoxic aminoglycoside stimuli. ( Jiang, X; Liu, K; Shi, C; Shi, L; Xu, Y; Yang, B; Yang, S; Yang, W, 2013) |
| "To determine the safety of gentamicin when used in a community setting to treat neonatal sepsis." | 3.79 | Risk of hearing loss in children exposed to gentamicin for the treatment of sepsis in young infancy: a community based cohort study in Pakistan. ( Ali, SA; Azam, I; Iftikhar, U; Saleem, S; Tikmani, SS; Zaidi, AK, 2013) |
| " Reactive oxygen species contribute to the formation of several types of cochlear injuries, including age-related hearing loss and gentamicin ototoxicity." | 3.77 | Protective role of Nrf2 in age-related hearing loss and gentamicin ototoxicity. ( Hara, A; Hoshino, T; Ishii, T; Nakayama, M; Nishimura, B; Shimizu, R; Tabuchi, K; Tanaka, S; Warabi, E; Yamamoto, M; Yanagawa, T, 2011) |
| "To characterize the extent that serum gentamicin concentrations are associated with hearing loss indicated by otoacoustic emission (OAE) screen failure in critically ill neonates receiving gentamicin in accordance with a high-dose, extended-interval dosing protocol." | 3.77 | Otoacoustic emission screen results in critically ill neonates who received gentamicin in the first week of life. ( Commers, AR; Cooper, AC; Finkelstein, M; Hoff, DS; Lipnik, PG; Tollefson, LM; Wilcox, RA, 2011) |
| "To compare proportions of the combined outcome of vertigo control and hearing preservation between intratympanic gentamicin injections and endolymphatic sac shunt surgery for intractable vertigo in Ménière's disease patients." | 3.76 | Outcomes of endolymphatic shunt surgery for Ménière's disease: comparison with intratympanic gentamicin on vertigo control and hearing loss. ( Berliner, K; Chung, J; Derebery, MJ; Fisher, LM; Green, K, 2010) |
| " In contrast, intratympanic gentamicin injection inducing permanent cell damage and mean hearing loss of 24dB correlated with a significant Birc5 downregulation in the ligament, nerve fibers and the organ of Corti." | 3.76 | Expression analysis suggests a potential cytoprotective role of Birc5 in the inner ear. ( Bier, C; Brieger, J; Brochhausen, C; Docter, D; Habtemichael, N; Heinrich, UR; Helling, K; Knauer, SK; Mann, WJ; Schmidtmann, I; Stauber, RH, 2010) |
| "Distortion product otoacoustic emission testing indicated gentamicin-induced hearing loss at 3, 4, 6 and 8 kHz in gentamicin-treated animals." | 3.75 | Protective effect of melatonin against gentamicin ototoxicity. ( Hua, QQ; Li, J; Tao, ZZ; Xiao, BK; Ye, LF; Yuan, YL; Zhou, XH, 2009) |
| "Administration of high-dose gentamicin for intractable Meniere's disease appears to be effective in achieving long-term control of vertigo." | 3.75 | High-dose intratympanic gentamicin instillations for treatment of Meniere's disease: long-term results. ( Hsieh, LC; Ko, YC; Lin, HC; Lin, LH; Shu, MT; Tsai, HT, 2009) |
| "To study the therapeutic effect of insulin-like growth factor-1 (IGF-1) injection into the inner ears through a scala tympani fenestration on sensorineural deafness in a guinea pig model of gentamicin-induced hearing loss." | 3.74 | [Therapeutic effect of insulin-like growth factor-1 injection into the inner ears through scala tympani fenestration on gentamicin-induced hearing loss in guinea pigs]. ( Chen, H; Guo, MH; Li, YH, 2008) |
| "To study the protective effect of local gene therapy with adeno-associated virus (AAV)-mediated neurotrophin-3 (NT-3) on the function and morphology of the cochlea of guinea pigs with gentamicin-induced hearing loss." | 3.74 | [Protective effect of adeno-associated virus-mediated neurotrophin-3 on the cochlea of guinea pigs with gentamicin-induced hearing loss]. ( Li, SL; Liu, H; Wang, XX; Yan, LY; Yao, XB; Zhu, HL, 2007) |
| "To determine whether patients with vestibulotoxic reactions to gentamicin have hearing thresholds worse than predicted by distributions of better-ear hearing thresholds in people of the same age and sex in the general population, and, if so, to measure the severity and audiometric pattern of that hearing loss." | 3.73 | Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. ( Black, FO; Dobie, RA; Pezsnecker, SC; Stallings, VL, 2006) |
| "To look for factors relating to the vertigo control and hearing changes after intratympanic injections of gentamicin (GM)." | 3.73 | Factors relating to the vertigo control and hearing changes following intratympanic gentamicin for intractable Ménière's disease. ( Fukushima, M; Horii, A; Kitahara, T; Kizawa, K; Kubo, T; Masumura, C; Mitani, K; Nakagawa, A; Nishiike, S; Nishimura, M; Saika, T; Sasaki, T; Uno, A, 2006) |
| "Gentamicin induced a consistent reduction in VOR responses and a progressive high-frequency hearing loss of 50-60 dB sound pressure level." | 3.72 | Protective effects of alpha-tocopherol against gentamicin-induced Oto-vestibulo toxicity: an experimental study. ( Ferraresi, A; Fetoni, AR; Paludetti, G; Scarano, E; Sergi, B; Troiani, D, 2003) |
| "Intratympanic or round window application of gentamicin is often used to alleviate disabling vertigo arising from unilateral Meniere's disease; however, treatment is often accompanied by hearing loss because the drug initially enters the cochlea before diffusing to the vestibular system." | 3.72 | Vestibular destruction by slow infusion of gentamicin into semicircular canals. ( Ding, D; Lii, M; Salvi, R; Zheng, XY, 2004) |
| "To determine the incidence, extent, and time course of hearing loss following instillation of intratympanic gentamicin using a predetermined fixed protocol for incapacitating unilateral Meniere's disease and to determine whether such loss is associated with any identifiable risk factors." | 3.71 | Hearing loss following intratympanic instillation of gentamicin for the treatment of unilateral Meniere's disease. ( Al-Abidi, A; Chen, JM; Kaplan, DM; Nedzelski, JM; Shipp, DB, 2002) |
| "Intratympanic gentamicin is used to control dizziness of Ménière's disease, with a low rate of morbidity and a high success rate." | 3.70 | Low-dose intratympanic gentamicin treatment for dizziness in Ménière's disease. ( Longridge, NS; Mallinson, AI, 2000) |
| "Guinea pigs received gentamicin to induce a profound hearing loss (61 dB auditory threshold shift at 18 kHz)." | 3.70 | Are aminoglycoside antibiotics excitotoxic? ( Schacht, J; Sha, SH, 1998) |
| "For the medically refractory Meniere's disease patient, treatment options include intratympanic steroid injection, endolymphatic sac decompression, medical or surgical labyrinthectomy, and vestibular nerve section." | 3.01 | Recent surgical advances and continued controversies in medically refractory Meniere's disease. ( Hong, RS; Lucas, JC, 2023) |
| " Therefore, we compared parenteral benzylpenicillin plus gentamicin with ceftriaxone as first-line treatment, assessing outcome and adverse events." | 2.84 | The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants <60 days of Age in Malawi. ( Banda, FM; Chiume, M; Dube, Q; Heyderman, RS; Mallewa, M; Molyneux, EM; Schwalbe, EC; Singini, I, 2017) |
| " The daily dosage of gentamicin amounted to 240 mg and that of vitamin E to 2800 mg." | 2.73 | Does vitamin E prevent gentamicin-induced ototoxicity? ( Davitashvili, O; Kevanishvili, Z; Kharkheli, E; Maglakelidze, T; Schacht, J, 2007) |
| "Netilmicin is a new semisynthetic aminoglycoside which was developed by Schering Corporation, USA, for the treatment of serious gram-negative and staphylococcal infections." | 2.65 | Netilmicin: chemical development and overview of clinical research. ( Herting, RL; Lane, AZ; Lorber, RR; Wright, JJ, 1980) |
| " Using stepwise discriminant analysis, we selected these factors with liver dysfunction and the serum urea nitrogen:serum creatinine ratio in a function that accurately discriminates between toxic and nontoxic patients." | 2.65 | Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. ( Lietman, PS; Moore, RD; Smith, CR, 1984) |
| "This article reviews recent advances in the protection from the adverse auditory or vestibular side effects associated with antibacterial treatment with aminoglycoside antibiotics." | 2.44 | Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. ( Chen, Y; Huang, WG; Qiu, JH; Schacht, J; Sha, SH; Wang, JL; Zha, DJ, 2007) |
| "Current drug candidates used to treat hearing loss commonly have low efficacy." | 1.48 | Novel SS-31 modified liposomes for improved protective efficacy of minocycline against drug-induced hearing loss. ( Gao, H; Hou, S; Kuang, X; Liu, H; Wang, Z; Yang, Y; Zhou, S, 2018) |
| "This retrospective cohort study conducted at 330 neonatal intensive care units (2002-2014) included inborn infants exposed to gentamicin with available hearing screen results, and excluded infants with incomplete dosing data and major congenital anomalies." | 1.48 | Evaluation of Gentamicin Exposure in the Neonatal Intensive Care Unit and Hearing Function at Discharge. ( Benjamin, DK; Bretzius, OM; Brown, N; Clark, RH; Fitz-Henley, JA; Gonzalez, D; Gray, KD; Hornik, CP; Puia-Dumitrescu, M; Smith, PB; Ssengonzi, R; Wechsler, CS, 2018) |
| "Gentamicin dosing was also calculated for each infant, including the total daily dose based on body mass (mg/kg/day), as well as the total number of treatment days." | 1.46 | Effect of gentamicin and levels of ambient sound on hearing screening outcomes in the neonatal intensive care unit: A pilot study. ( Coopersmith, N; Cross, CP; Durham, H; Ettinger, O; Galati, J; Garinis, AC; Hart, C; Liao, S; Lubianski, T; MacArthur, C; Mace, JC; McEvoy, C; McEvoy, L; Middaugh, JL; Moneta, L; Nold, C; Riddle, A; Steyger, PS; Vigo, N; Wood, AM, 2017) |
| "All VLBW infants examined for hearing impairment were included and data were retrieved retrospectively and analyzed for neonatal risk factors using logistic regression." | 1.46 | Prevalence and independent risk factors for hearing impairment among very low birth weight infants. ( Chiang, MC; Chu, SM; Fu, RH; Hsu, JF; Lien, R; Wang, CH; Yang, CY, 2017) |
| "Gentamicin was used to induce neuronal hearing loss in mice, in the presence and absence of FA, followed by assessments of auditory brainstem response (ABR) and distortion product optoacoustic emissions (DPOAE) amplitude." | 1.46 | Ferulic acid promotes survival and differentiation of neural stem cells to prevent gentamicin-induced neuronal hearing loss. ( Cui, X; Gu, L; Li, X; Wei, W; Yang, J, 2017) |
| "Neuronal hearing loss has become a prevalent health problem." | 1.46 | Arctigenin protects against neuronal hearing loss by promoting neural stem cell survival and differentiation. ( Chen, M; Ding, Y; Huang, X; Wang, Q, 2017) |
| "Efinaconazole 10 % solution is a new triazole antifungal agent developed for the topical treatment of fungal infections of the nails." | 1.43 | Effect of intratympanic application of efinaconazole 10 % solution in the guinea pig. ( Arakawa, K; Hidaka, H; Honkura, Y; Ikeda, R; Katori, Y; Kawase, T; Nomura, K; Oshima, H, 2016) |
| " This study investigated if these adverse effects vary according to the circadian time of its administration." | 1.42 | Circadian variation of gentamicin toxicity in rats. ( McKinney, W; Smolensky, MH; Yonovitz, A, 2015) |
| "Tinnitus was the first and the predominant symptom in 140 patients (89." | 1.40 | Ototoxicity in Nigeria: why it persists. ( Ahmad, BM; Bakari, A; Kokong, DD, 2014) |
| " Based on these findings, we propose changes in gentamicin dosing interval and trough level monitoring to minimize the risk of potentially toxic levels in cooled newborns." | 1.39 | Factors associated with permanent hearing impairment in infants treated with therapeutic hypothermia. ( Gill, H; Jary, S; Liu, X; Sabir, H; Smit, E; Thoresen, M, 2013) |
| "Gentamicin sulfate is a potent aminoglycoside antibiotic associated with serious side effects, including ototoxicity." | 1.38 | Garlic-supplemented diet attenuates gentamicin-induced ototoxicity: an experimental study. ( Akinci, H; Balbaloglu, E; Uzun, L, 2012) |
| " Toxicity is dose related, but some patients may still develop hearing loss even under safe dosage." | 1.37 | Transient ischemia/hypoxia enhances gentamicin ototoxicity via caspase-dependent cell death pathway. ( Hsu, CJ; Kao, MC; Lai, CH; Lin, CD; Lin, CW; Lin, CY; Tang, CH; Tsai, MH; Wei, IH, 2011) |
| "Vancomycin, by contrast, was associated with ototoxicity." | 1.37 | Are gentamicin and/or vancomycin associated with ototoxicity in the neonate? A retrospective audit. ( Begg, EJ; Borrie, TL; Darlow, BA; Lynn, AM; Robertshawe, BJ; Vella-Brincat, JW, 2011) |
| "Although most studies have identified damage in the cochlea and semicircular canals as the primary sites of aminoglycoside toxicity, little attention has been devoted to the toxic effects on the otolithic organs." | 1.36 | A novel inner ear monitoring system for evaluating ototoxicity of gentamicin eardrops in guinea pigs. ( Liu, SH; Yang, TH; Young, YH, 2010) |
| "Gentamicin (100mg/mL) was the agent of choice as it is an extensively-studied human ototoxin." | 1.36 | Physiological dimensions of ototoxic responses in a model fish species. ( Brack, CL; Ramcharitar, JU, 2010) |
| "Hearing and balance receptors in the inner ear are highly susceptible to damage caused by a wide variety of toxic substances, including aminoglycosides." | 1.36 | Comparison of different aminoglycoside antibiotic treatments to refine ototoxicity studies in adult mice. ( Cediel, R; Contreras, J; Murillo-Cuesta, S; Varela-Nieto, I, 2010) |
| "These results suggest that genetic susceptibility is not a major factor in the high rate of gentamicin ototoxicity in this population sample." | 1.35 | Aminoglycoside ototoxicity in Nicaraguan children: patient risk factors and mitochondrial DNA results. ( Greinwald, JH; Guo, Y; Saunders, JE; Vaz, S, 2009) |
| "Gentamicin application is an important therapeutic option for Ménière's disease." | 1.35 | Gentamicin increases nitric oxide production and induces hearing loss in guinea pigs. ( Brieger, J; Heinrich, UR; Helling, K; Li, H; Mann, WJ; Schmidtmann, I; Sifferath, M, 2008) |
| " However, severe toxic side effects along with the reduced suppression efficiency at subtoxic doses limit the use of gentamicin for suppression therapy." | 1.35 | Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. ( Baasov, T; Belakhov, V; Ben-Yosef, T; Chen, F; Cherniavsky, M; Hainrichson, M; Nudelman, I; Pilch, DS; Rebibo-Sabbah, A; Schacht, J, 2009) |
| "Gentamicin exposure may enhance transiently the expression of Otoferlin in ribbon synapse in C57BL/6J mice." | 1.35 | A pattern of otoferlin expression interrupted by gentamicin exposure in ribbon synapse of inner hair cell in C57BL/6J mice. ( Ke, L; ShuNa, L; Zhong, R, 2009) |
| "Gentamicin is a widely used ototoxic agent." | 1.33 | Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss. ( Chen, S; Esteban-Cruciani, N; Fernandez-Zapico, ME; Kalinec, F; Kalinec, GM; Urrutia, R, 2005) |
| " Aminoglycosides are commonly used antibiotics, with the undesirable side-effect of ototoxicity." | 1.33 | Efferent-mediated adaptation of the DPOAE as a predictor of aminoglycoside toxicity. ( Dolan, DF; Halsey, K; Skjönsberg, A; Ulfendahl, M, 2005) |
| "Histological evaluation of vestibular and cochlear damage was performed on Mongolian gerbils after a known dosage of gentamicin in different delivery vehicles." | 1.32 | Direct round window application of gentamicin with varying delivery vehicles: a comparison of ototoxicity. ( Pack, A; Sheppard, WM; Slepecky, N; Wanamaker, HH; Yamamoto, S, 2004) |
| " Eleven (GMFF-group) animals received the same dose of GM but 2 days prior were dosed with FF (10 mg/kg/day) for 2 weeks." | 1.32 | Flavanoid of Drynaria fortunei protects against gentamicin ototoxicity. ( Johnson, F; Li, F; Long, M; Luft, B; Qiu, D; Smouha, EE, 2004) |
| "treated with gentamicin alone at a dose of 100 mg/kg body weight (IM); and group D (n = 10), treated with gentamicin at the same dose plus alpha-tocopherol acetate at dose of 100 mg/kg body weight (IM)." | 1.32 | alpha-Tocopherol protective effects on gentamicin ototoxicity: an experimental study. ( Ferraresi, A; Fetoni, AR; Paludetti, G; Sergi, B; Troiani, D, 2004) |
| "Gentamicin (26." | 1.31 | Intratympanic gentamicin for the treatment of unilateral Meniere's disease. ( Chen, JM; Kaplan, DM; Nedzelski, JM; Shipp, DB, 2000) |
| "Gentamicin was applied to the right ear of chinchillas either through a transtympanic approach or in a sustained-release device." | 1.31 | Transtympanic versus sustained-release administration of gentamicin: kinetics, morphology, and function. ( Allen, K; Gottshall, K; Hoffer, ME; Kopke, RD; Weisskopf, P; Wester, D, 2001) |
| " Thus, it remains to be determined whether presbyacusis sensitizes those hair cells which it does not destroy to toxic damage." | 1.28 | Screening for aminoglycoside auditory toxicity in the old. ( Cheung, R; Clark, P; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Nicholson, PW; O'Neill, CJ, 1990) |
| "Netilmicin was administered intramuscularly in a dose of 2 mg/kg body weight every 8 hours." | 1.26 | Netilmicin therapy of patients with septicaemia and other severe infections. ( Brandenhoff, P; Bretlau, P; Gammelgaard, PA; Jensen, SH; Rasmussen, F; Stafanger, G; Thomsen, VF, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (8.70) | 18.7374 |
| 1990's | 6 (4.35) | 18.2507 |
| 2000's | 48 (34.78) | 29.6817 |
| 2010's | 64 (46.38) | 24.3611 |
| 2020's | 8 (5.80) | 2.80 |
| Authors | Studies |
|---|---|
| Niu, P | 1 |
| Sun, Y | 3 |
| Wang, S | 1 |
| Li, G | 1 |
| Tang, X | 1 |
| Sun, J | 2 |
| Pan, C | 1 |
| Li, J | 3 |
| Liu, C | 1 |
| Müller, U | 1 |
| Zhao, B | 1 |
| Li, H | 4 |
| Oh, SH | 1 |
| Shin, HC | 1 |
| Suh, MW | 2 |
| Chant, K | 1 |
| Bitner-Glindzicz, M | 1 |
| Marlow, N | 1 |
| Lucas, JC | 1 |
| Hong, RS | 1 |
| Chang, SY | 1 |
| Lee, MY | 1 |
| Chung, PS | 1 |
| Kim, S | 1 |
| Choi, B | 1 |
| Rhee, CK | 1 |
| Jung, JY | 1 |
| Molnár, A | 1 |
| Maihoub, S | 1 |
| Gáborján, A | 1 |
| Tamás, L | 1 |
| Szirmai, Á | 1 |
| Li, X | 3 |
| Wang, Y | 1 |
| Xu, F | 1 |
| Zhang, F | 1 |
| Xu, Y | 3 |
| Tang, L | 1 |
| Webster, TJ | 1 |
| Wu, Y | 1 |
| Zhou, Y | 1 |
| Yu, J | 1 |
| Song, Z | 1 |
| Dai, C | 2 |
| Wang, J | 1 |
| Garinis, AC | 2 |
| Liao, S | 2 |
| Cross, CP | 2 |
| Galati, J | 1 |
| Middaugh, JL | 1 |
| Mace, JC | 1 |
| Wood, AM | 1 |
| McEvoy, L | 1 |
| Moneta, L | 1 |
| Lubianski, T | 1 |
| Coopersmith, N | 1 |
| Vigo, N | 1 |
| Hart, C | 1 |
| Riddle, A | 1 |
| Ettinger, O | 1 |
| Nold, C | 1 |
| Durham, H | 1 |
| MacArthur, C | 1 |
| McEvoy, C | 1 |
| Steyger, PS | 4 |
| Edizer, DT | 1 |
| Yigit, O | 1 |
| Cinar, Z | 1 |
| Gul, M | 1 |
| Kara, E | 1 |
| Yigitcan, B | 1 |
| Hayır, D | 1 |
| Atas, A | 2 |
| Wang, Z | 3 |
| Kuang, X | 3 |
| Shi, J | 1 |
| Guo, W | 2 |
| Liu, H | 4 |
| Paterson, S | 1 |
| Gu, L | 1 |
| Cui, X | 1 |
| Wei, W | 1 |
| Yang, J | 1 |
| Zhou, S | 2 |
| Hou, S | 1 |
| Yang, Y | 2 |
| Gao, H | 1 |
| Zhuang, HY | 1 |
| Xiong, GX | 1 |
| Wu, X | 1 |
| Chen, XH | 1 |
| Hong, J | 1 |
| Chen, Y | 2 |
| Zhang, Y | 2 |
| Ren, L | 1 |
| Yang, L | 1 |
| Shi, L | 5 |
| Li, A | 1 |
| Zhang, T | 1 |
| Dai, P | 1 |
| Puia-Dumitrescu, M | 1 |
| Bretzius, OM | 1 |
| Brown, N | 1 |
| Fitz-Henley, JA | 1 |
| Ssengonzi, R | 1 |
| Wechsler, CS | 1 |
| Gray, KD | 1 |
| Benjamin, DK | 1 |
| Smith, PB | 1 |
| Clark, RH | 1 |
| Gonzalez, D | 1 |
| Hornik, CP | 1 |
| Wu, Q | 1 |
| Sha, Y | 1 |
| Kucharava, K | 1 |
| Sekulic-Jablanovic, M | 1 |
| Horvath, L | 1 |
| Bodmer, D | 2 |
| Petkovic, V | 1 |
| Ishikawa, M | 1 |
| García-Mateo, N | 1 |
| Čusak, A | 1 |
| López-Hernández, I | 1 |
| Fernández-Martínez, M | 1 |
| Müller, M | 1 |
| Rüttiger, L | 1 |
| Singer, W | 1 |
| Löwenheim, H | 1 |
| Kosec, G | 1 |
| Fujs, Š | 1 |
| Martínez-Martínez, L | 1 |
| Schimmang, T | 1 |
| Petković, H | 1 |
| Knipper, M | 1 |
| Durán-Alonso, MB | 1 |
| Jiang, M | 1 |
| Johnson, A | 1 |
| Karasawa, T | 2 |
| Meier, WB | 1 |
| Taghizadeh, F | 1 |
| Kachelmeier, A | 1 |
| Liu, K | 2 |
| Jiang, X | 1 |
| Shi, C | 2 |
| Yang, B | 1 |
| Yang, W | 1 |
| Yang, S | 2 |
| Smit, E | 1 |
| Liu, X | 1 |
| Gill, H | 1 |
| Sabir, H | 1 |
| Jary, S | 1 |
| Thoresen, M | 1 |
| King, EB | 1 |
| Salt, AN | 1 |
| Kel, GE | 1 |
| Eastwood, HT | 1 |
| O'Leary, SJ | 1 |
| Tian, CJ | 1 |
| Kim, SW | 2 |
| Kim, YJ | 1 |
| Lim, HJ | 1 |
| Park, R | 1 |
| So, HS | 1 |
| Choung, YH | 2 |
| Iftikhar, U | 1 |
| Ali, SA | 1 |
| Tikmani, SS | 1 |
| Azam, I | 1 |
| Saleem, S | 1 |
| Zaidi, AK | 1 |
| MacKeith, SA | 1 |
| Whiteside, OJ | 1 |
| Mawby, T | 1 |
| Bottrill, ID | 1 |
| Ojano-Dirain, CP | 1 |
| Antonelli, PJ | 1 |
| Le Prell, CG | 1 |
| Wang, X | 1 |
| Ji, F | 1 |
| Hou, Z | 1 |
| Ruhl, DS | 1 |
| Cable, BB | 1 |
| Martell, DW | 1 |
| Kokong, DD | 1 |
| Bakari, A | 1 |
| Ahmad, BM | 1 |
| Bremer, HG | 1 |
| van Rooy, I | 1 |
| Pullens, B | 1 |
| Colijn, C | 1 |
| Stegeman, I | 1 |
| van der Zaag-Loonen, HJ | 1 |
| van Benthem, PP | 1 |
| Klis, SF | 1 |
| Grolman, W | 1 |
| Bruintjes, TD | 1 |
| Brand, Y | 1 |
| Radojevic, V | 1 |
| Sung, M | 1 |
| Wei, E | 1 |
| Setz, C | 1 |
| Glutz, A | 1 |
| Leitmeyer, K | 1 |
| Quan, Y | 1 |
| Xia, L | 1 |
| Shao, J | 1 |
| Yin, S | 1 |
| Cheng, CY | 1 |
| Xia, W | 1 |
| Gao, WQ | 2 |
| McKinney, W | 1 |
| Yonovitz, A | 1 |
| Smolensky, MH | 1 |
| Arakawa, K | 1 |
| Nomura, K | 1 |
| Oshima, H | 1 |
| Honkura, Y | 1 |
| Ikeda, R | 1 |
| Hidaka, H | 1 |
| Kawase, T | 1 |
| Katori, Y | 1 |
| El-Barbary, MN | 1 |
| Ismail, RI | 1 |
| Ibrahim, AA | 1 |
| Urdang, ZD | 1 |
| Srikanth, P | 1 |
| D'yakonova, IN | 1 |
| Kamkina, OV | 1 |
| Ishanova, YS | 1 |
| Rakhmanova, IV | 1 |
| Burmistrova, DS | 1 |
| Li, S | 1 |
| Hang, L | 1 |
| Ma, Y | 1 |
| Aladag, I | 1 |
| Guven, M | 1 |
| Songu, M | 1 |
| Li, BB | 1 |
| Wu, J | 1 |
| Chen, J | 1 |
| Chen, H | 2 |
| Li, YH | 2 |
| Patel, M | 1 |
| Agarwal, K | 1 |
| Arshad, Q | 1 |
| Hariri, M | 1 |
| Rea, P | 1 |
| Seemungal, BM | 1 |
| Golding, JF | 1 |
| Harcourt, JP | 1 |
| Bronstein, AM | 1 |
| Huang, X | 1 |
| Chen, M | 1 |
| Ding, Y | 1 |
| Wang, Q | 2 |
| Han, Z | 1 |
| Wang, CP | 1 |
| Cong, N | 1 |
| Gu, YY | 1 |
| Ma, R | 1 |
| Chi, FL | 2 |
| Wang, CH | 1 |
| Yang, CY | 1 |
| Lien, R | 1 |
| Chu, SM | 1 |
| Hsu, JF | 1 |
| Fu, RH | 1 |
| Chiang, MC | 1 |
| Molyneux, EM | 1 |
| Dube, Q | 1 |
| Banda, FM | 1 |
| Chiume, M | 1 |
| Singini, I | 1 |
| Mallewa, M | 1 |
| Schwalbe, EC | 1 |
| Heyderman, RS | 1 |
| McGlone, A | 1 |
| Cranswick, N | 1 |
| Kawamoto, K | 1 |
| Izumikawa, M | 1 |
| Beyer, LA | 1 |
| Atkin, GM | 1 |
| Raphael, Y | 1 |
| Ye, LF | 1 |
| Tao, ZZ | 1 |
| Hua, QQ | 1 |
| Xiao, BK | 1 |
| Zhou, XH | 1 |
| Yuan, YL | 1 |
| Saunders, JE | 2 |
| Greinwald, JH | 3 |
| Vaz, S | 2 |
| Guo, Y | 2 |
| Nudelman, I | 1 |
| Rebibo-Sabbah, A | 1 |
| Cherniavsky, M | 1 |
| Belakhov, V | 1 |
| Hainrichson, M | 1 |
| Chen, F | 1 |
| Schacht, J | 7 |
| Pilch, DS | 1 |
| Ben-Yosef, T | 1 |
| Baasov, T | 1 |
| Behnoud, F | 2 |
| Davoudpur, K | 1 |
| Goodarzi, MT | 1 |
| Murillo-Cuesta, S | 1 |
| Contreras, J | 1 |
| Cediel, R | 1 |
| Varela-Nieto, I | 1 |
| ShuNa, L | 1 |
| Zhong, R | 1 |
| Ke, L | 1 |
| Hsieh, LC | 1 |
| Lin, HC | 1 |
| Tsai, HT | 1 |
| Ko, YC | 1 |
| Shu, MT | 1 |
| Lin, LH | 1 |
| de Klaver, PA | 1 |
| Koning, Jd | 1 |
| Janssen, RP | 1 |
| Derijks, LJ | 1 |
| Ramcharitar, JU | 1 |
| Brack, CL | 1 |
| Johnson, RF | 1 |
| Cohen, AP | 1 |
| Schibler, K | 1 |
| Derebery, MJ | 1 |
| Fisher, LM | 1 |
| Berliner, K | 1 |
| Chung, J | 1 |
| Green, K | 1 |
| Naeem, M | 1 |
| Rahimnajjad, NA | 1 |
| Yang, TH | 1 |
| Liu, SH | 1 |
| Young, YH | 1 |
| Habtemichael, N | 1 |
| Heinrich, UR | 2 |
| Knauer, SK | 1 |
| Schmidtmann, I | 2 |
| Bier, C | 1 |
| Docter, D | 1 |
| Brochhausen, C | 1 |
| Helling, K | 2 |
| Brieger, J | 2 |
| Stauber, RH | 1 |
| Mann, WJ | 2 |
| Polesskaya, O | 1 |
| Cunningham, LL | 1 |
| Francis, SP | 1 |
| Luebke, AE | 1 |
| Zhu, X | 1 |
| Collins, D | 1 |
| Vasilyeva, ON | 1 |
| Sahler, J | 1 |
| Desmet, EA | 1 |
| Gelbard, HA | 1 |
| Maggirwar, SB | 1 |
| Walton, JP | 1 |
| Frisina, RD | 1 |
| Dewhurst, S | 1 |
| Kang, XD | 1 |
| Cheng, NJ | 1 |
| Liang, GQ | 1 |
| Wu, PL | 1 |
| Yu, YQ | 1 |
| Sun, X | 1 |
| Vella-Brincat, JW | 1 |
| Begg, EJ | 1 |
| Robertshawe, BJ | 1 |
| Lynn, AM | 1 |
| Borrie, TL | 1 |
| Darlow, BA | 1 |
| Lin, CD | 1 |
| Kao, MC | 1 |
| Tsai, MH | 2 |
| Lai, CH | 1 |
| Wei, IH | 1 |
| Tang, CH | 1 |
| Lin, CW | 1 |
| Hsu, CJ | 1 |
| Lin, CY | 1 |
| Tian, C | 1 |
| Min, JY | 1 |
| Lee, HK | 1 |
| Park, SN | 1 |
| Lee, JB | 1 |
| Park, K | 1 |
| Singh Chauhan, R | 1 |
| Saxena, RK | 1 |
| Varshey, S | 1 |
| David, LL | 1 |
| Cooper, AC | 1 |
| Commers, AR | 1 |
| Finkelstein, M | 1 |
| Lipnik, PG | 1 |
| Tollefson, LM | 1 |
| Wilcox, RA | 1 |
| Hoff, DS | 1 |
| Hoshino, T | 1 |
| Tabuchi, K | 1 |
| Nishimura, B | 1 |
| Tanaka, S | 1 |
| Nakayama, M | 1 |
| Ishii, T | 1 |
| Warabi, E | 1 |
| Yanagawa, T | 1 |
| Shimizu, R | 1 |
| Yamamoto, M | 1 |
| Hara, A | 1 |
| Bas, E | 1 |
| Van De Water, TR | 1 |
| Gupta, C | 1 |
| Dinh, J | 1 |
| Vu, L | 1 |
| Martínez-Soriano, F | 1 |
| Láinez, JM | 1 |
| Marco, J | 1 |
| Uzun, L | 1 |
| Balbaloglu, E | 1 |
| Akinci, H | 1 |
| Pacheu-Grau, D | 1 |
| Pérez-Delgado, L | 1 |
| Gómez-Díaz, C | 1 |
| Fraile-Rodrigo, J | 1 |
| Montoya, J | 1 |
| Ruiz-Pesini, E | 1 |
| Loock, JW | 1 |
| Jankauskas, SS | 1 |
| Plotnikov, EY | 1 |
| Morosanova, MA | 1 |
| Pevzner, IB | 1 |
| Zorova, LD | 1 |
| Skulachev, VP | 1 |
| Zorov, DB | 1 |
| Chen, L | 1 |
| Xiong, S | 1 |
| Liu, Y | 1 |
| Shang, X | 1 |
| Hu, P | 1 |
| Lai, R | 1 |
| Xie, D | 1 |
| Gabra, N | 1 |
| Saliba, I | 1 |
| Berryhill, WE | 1 |
| Graham, MD | 1 |
| Brushwood, DB | 1 |
| Allen, WL | 1 |
| Fetoni, AR | 3 |
| Sergi, B | 3 |
| Scarano, E | 1 |
| Paludetti, G | 3 |
| Ferraresi, A | 3 |
| Troiani, D | 3 |
| Wang, AM | 1 |
| Sha, SH | 4 |
| Lesniak, W | 1 |
| Shou, J | 1 |
| Zheng, JL | 1 |
| Matz, G | 1 |
| Rybak, L | 1 |
| Roland, PS | 1 |
| Hannley, M | 1 |
| Friedman, R | 1 |
| Manolidis, S | 1 |
| Stewart, MG | 1 |
| Weber, P | 1 |
| Owens, F | 1 |
| Lii, M | 1 |
| Ding, D | 2 |
| Zheng, XY | 1 |
| Salvi, R | 2 |
| Azzena, GB | 1 |
| Maurizi, M | 1 |
| Chia, SH | 1 |
| Gamst, AC | 1 |
| Anderson, JP | 1 |
| Harris, JP | 1 |
| Perez, R | 1 |
| Chen, JM | 3 |
| Nedzelski, JM | 3 |
| Long, M | 1 |
| Smouha, EE | 1 |
| Qiu, D | 1 |
| Li, F | 1 |
| Johnson, F | 1 |
| Luft, B | 1 |
| Corbacella, E | 1 |
| Lanzoni, I | 1 |
| Previati, M | 1 |
| Sheppard, WM | 1 |
| Wanamaker, HH | 1 |
| Pack, A | 1 |
| Yamamoto, S | 1 |
| Slepecky, N | 1 |
| Unal, OF | 1 |
| Ghoreishi, SM | 1 |
| Akyürek, N | 1 |
| Akyol, G | 1 |
| Gürsel, B | 1 |
| Yarin, YM | 1 |
| Amarjargal, N | 1 |
| Fuchs, J | 1 |
| Haupt, H | 1 |
| Mazurek, B | 1 |
| Morozova, SV | 1 |
| Gross, J | 1 |
| Halsey, K | 1 |
| Skjönsberg, A | 1 |
| Ulfendahl, M | 1 |
| Dolan, DF | 1 |
| Kalinec, GM | 1 |
| Fernandez-Zapico, ME | 1 |
| Urrutia, R | 1 |
| Esteban-Cruciani, N | 1 |
| Chen, S | 1 |
| Kalinec, F | 1 |
| Ishiyama, G | 1 |
| Finn, M | 1 |
| Lopez, I | 1 |
| Tang, Y | 1 |
| Baloh, RW | 1 |
| Ishiyama, A | 1 |
| Flanagan, S | 1 |
| Mukherjee, P | 1 |
| Tonkin, J | 1 |
| Dobie, RA | 1 |
| Black, FO | 1 |
| Pezsnecker, SC | 1 |
| Stallings, VL | 1 |
| Ghossaini, SN | 1 |
| Wazen, JJ | 1 |
| Qiu, JH | 2 |
| Horii, A | 1 |
| Saika, T | 1 |
| Uno, A | 1 |
| Nishiike, S | 1 |
| Mitani, K | 1 |
| Nishimura, M | 1 |
| Kitahara, T | 1 |
| Fukushima, M | 1 |
| Nakagawa, A | 1 |
| Masumura, C | 1 |
| Sasaki, T | 1 |
| Kizawa, K | 1 |
| Kubo, T | 1 |
| Huang, WG | 1 |
| Zha, DJ | 1 |
| Wang, JL | 1 |
| Lai, J | 1 |
| Morin, L | 1 |
| Mojica, K | 1 |
| Feldman, L | 1 |
| Efrati, S | 1 |
| Eviatar, E | 1 |
| Abramsohn, R | 1 |
| Yarovoy, I | 1 |
| Gersch, E | 1 |
| Averbukh, Z | 1 |
| Weissgarten, J | 1 |
| Kharkheli, E | 1 |
| Kevanishvili, Z | 1 |
| Maglakelidze, T | 1 |
| Davitashvili, O | 1 |
| Tepel, M | 1 |
| Rourke, T | 1 |
| Yao, XB | 1 |
| Li, SL | 1 |
| Zhu, HL | 1 |
| Wang, XX | 1 |
| Yan, LY | 1 |
| Guo, MH | 1 |
| Liu, HY | 1 |
| Gao, WY | 1 |
| Sifferath, M | 1 |
| Davey, PG | 2 |
| Jabeen, FJ | 1 |
| Harpur, ES | 2 |
| Shenoi, PM | 2 |
| Geddes, AM | 2 |
| Tablan, OC | 1 |
| Reyes, MP | 1 |
| Rintelmann, WF | 1 |
| Lerner, AM | 1 |
| Moore, RD | 1 |
| Smith, CR | 1 |
| Lietman, PS | 1 |
| Theopold, HM | 1 |
| Crifo, S | 1 |
| Antonelli, M | 1 |
| Gagliardi, M | 1 |
| Lucarelli, N | 1 |
| Marcolini, P | 1 |
| Brandenhoff, P | 1 |
| Stafanger, G | 1 |
| Gammelgaard, PA | 1 |
| Rasmussen, F | 1 |
| Jensen, SH | 1 |
| Bretlau, P | 1 |
| Thomsen, VF | 1 |
| Herting, RL | 1 |
| Lane, AZ | 1 |
| Lorber, RR | 1 |
| Wright, JJ | 1 |
| Jabeen, F | 1 |
| Chodynicki, S | 1 |
| Musierowicz, A | 1 |
| Garetz, SL | 1 |
| Altschuler, RA | 1 |
| Révai, K | 1 |
| Katona, G | 1 |
| Pytel, J | 1 |
| Czinner, A | 1 |
| Pataki, L | 1 |
| Chayasirisobhon, S | 1 |
| Yu, L | 1 |
| Griggs, L | 1 |
| Westmoreland, SJ | 1 |
| Leu, N | 1 |
| Longridge, NS | 1 |
| Mallinson, AI | 1 |
| Kaplan, DM | 2 |
| Shipp, DB | 2 |
| Hoffer, ME | 1 |
| Allen, K | 1 |
| Kopke, RD | 1 |
| Weisskopf, P | 1 |
| Gottshall, K | 1 |
| Wester, D | 1 |
| Al-Abidi, A | 1 |
| Forman-Franco, B | 1 |
| Abramson, AL | 1 |
| Gorvoy, JD | 1 |
| Stein, T | 1 |
| Sward, M | 1 |
| Ziemski, Z | 1 |
| Zajac, J | 1 |
| Przyjałgowska, M | 1 |
| Kowalewska, M | 1 |
| Fausti, SA | 1 |
| Henry, JA | 1 |
| Schaffer, HI | 1 |
| Olson, DJ | 1 |
| Frey, RH | 1 |
| McDonald, WJ | 1 |
| Cheung, R | 1 |
| Clark, P | 1 |
| Nicholson, PW | 1 |
| Deshmukh, AA | 1 |
| O'Neill, CJ | 1 |
| Dobbs, SM | 1 |
| Dobbs, RJ | 1 |
| Lin, WS | 1 |
| Song, XZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial[NCT00802529] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hearing was measured as ipsilesional pure-tone threshold at Baseline, 1month, 2months, 6months, 12month, 18months and 24 months follow-up. Hearing level was taken as the average threshold across 0.5, 1, 2 and 3KHz. (NCT00802529)
Timeframe: Baseline, 1,2,6,12,18 and 24months after initial treatment
| Intervention | dB (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | 1month | 2months | 6months | 12months | 18months | 24months | |
| Gentamicin | 51.5 | 52.18 | 48.99 | 45.48 | 47.34 | 44.82 | 49.1 |
| Steroid (Methylprednisolone) | 53.25 | 49.29 | 49.83 | 46.67 | 47.02 | 48.44 | 46.9 |
"Speech discrimination was measured at Baseline, 1month, 2months, 6months, 12month and 24 months follow-up.~Speech discrimination was assessed by means of ipsilesional suprathreshold word recognition (%). Arthur Boothroyd's isophonemic word lists (AB wordlists, Guymark, Southampton) comprising sets of 10 words were played to the ipsilesional ear at the low-frequency pure-tone threshold of 0·5, 1 and 2 kHz +30dB with masking sound in the contralesional ear if necessary. The formula for masking level was: low-frequency pure-tone threshold in ipsilesional ear - bone conduction mean threshold (0·5, 1 and 2KHz) in contralesional ear - 40dB. Speech loudness and masking were rounded to the nearest 5dB. Step increments and decrements of 10dB for speech loudness and masking were used to attain the maximum speech discrimination score." (NCT00802529)
Timeframe: Baseline, 1,2,6,12 and 24months after initial treatment
| Intervention | Percentage correct (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | 1month | 2months | 6months | 12months | 24months | |
| Gentamicin | 72.10 | 69.43 | 74.31 | 76.35 | 71.58 | 64.99 |
| Steroid (Methylprednisolone) | 64.97 | 71.78 | 76.10 | 75.63 | 73.43 | 76.32 |
The number of vertigo attacks between 18-24months follow-up were taken retrospectively during a face-to-face appointment at 24 months follow-up and compared to 6 month pre-enrollment baseline (as per Committee on Hearing and Equilibrium guidelines). (NCT00802529)
Timeframe: 6month pre-enrollment baseline, 18-24 months after initial treatment
| Intervention | Vertigo Attacks (Mean) | |
|---|---|---|
| Baseline | 18-24months | |
| Gentamicin | 19.93 | 2.5 |
| Steroid (Methylprednisolone) | 16.4 | 1.6 |
8 reviews available for gentamicin and Hearing Loss
| Article | Year |
|---|---|
Recent surgical advances and continued controversies in medically refractory Meniere's disease.
Topics: Deafness; Ear, Inner; Gentamicins; Hearing Loss; Humans; Meniere Disease; Vertigo | 2023 |
Evidence behind the WHO guidelines: Hospital care for children: what is the evidence of safety of gentamicin use in children?
Topics: Anti-Bacterial Agents; Bacterial Infections; Child; Developing Countries; Evidence-Based Medicine; E | 2008 |
Chemical and physical labyrinthectomy for Meniere's disease.
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Ear, Inner; Ear, Middle; Electrony | 2002 |
Ototoxicity of ototopical antibiotic drops in humans.
Topics: Administration, Topical; Anti-Bacterial Agents; Cochlea; Gentamicins; Hearing Loss; Humans; Neomycin | 2004 |
Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis.
Topics: Anti-Bacterial Agents; Catheter Ablation; Gentamicins; Hearing Loss; Humans; Meniere Disease; Treatm | 2004 |
An update on the surgical treatment of Ménière's diseases.
Topics: Anti-Bacterial Agents; Ear, Inner; Endolymphatic Sac; Gentamicins; Hearing Loss; Humans; Meniere Dis | 2006 |
Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Cochlea; Gentamicins; Hearing Loss; Humans; Randomized Cont | 2007 |
Prevalence and etiology of hearing loss in rural Nicaraguan children.
Topics: Child; Connexin 26; Connexins; Female; Genetic Predisposition to Disease; Gentamicins; Hearing Loss; | 2007 |
12 trials available for gentamicin and Hearing Loss
| Article | Year |
|---|---|
Intratympanic gentamicin treatment for Ménière's disease: a randomized, double-blind, placebo-controlled trial on dose efficacy - results of a prematurely ended study.
Topics: Adult; Aged; Anti-Bacterial Agents; Audiometry, Pure-Tone; Dose-Response Relationship, Drug; Double- | 2014 |
Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Double-Blind Method; Female; Gentamicins; Hearing L | 2016 |
The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants <60 days of Age in Malawi.
Topics: Anti-Bacterial Agents; Bilirubin; Ceftriaxone; Gentamicins; Hearing Loss; Humans; Infant; Infant, Ne | 2017 |
Can aspirin protect or at least attenuate gentamicin ototoxicity in humans?
Topics: Anti-Bacterial Agents; Aspirin; Double-Blind Method; Female; Gentamicins; Hearing Loss; Humans; Male | 2009 |
A randomised controlled trial of active chronic otitis media comparing courses of eardrops versus one-off topical treatments suitable for primary, secondary and tertiary healthcare settings.
Topics: Acetic Acid; Administration, Topical; Adult; Analysis of Variance; Anti-Infective Agents; Audiometry | 2012 |
Aspirin to prevent gentamicin-induced hearing loss.
Topics: Adult; Anti-Bacterial Agents; Antioxidants; Aspirin; Cyclooxygenase Inhibitors; Double-Blind Method; | 2006 |
Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine.
Topics: Acetylcysteine; Administration, Oral; Aged; Aminoglycosides; Anti-Bacterial Agents; Antioxidants; Ba | 2007 |
Does vitamin E prevent gentamicin-induced ototoxicity?
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Double-Blind Method; Female; Gentamicins; Hearing Lo | 2007 |
A controlled study of the reliability of pure tone audiometry for the detection of gentamicin auditory toxicity.
Topics: Adult; Audiometry; Audiometry, Pure-Tone; Clinical Trials as Topic; Female; Gentamicins; Hearing Los | 1983 |
Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.
Topics: Amikacin; Body Temperature; Female; Gentamicins; Hearing Loss; Humans; Kanamycin; Male; Probability; | 1984 |
Netilmicin: chemical development and overview of clinical research.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Child; Child, Preschool; Clinical Trials as Topic; Dr | 1980 |
Recording of brainstem evoked potentials and their association with gentamicin in neonates.
Topics: Anti-Bacterial Agents; Evoked Potentials, Auditory, Brain Stem; Female; Gentamicins; Gestational Age | 1996 |
118 other studies available for gentamicin and Hearing Loss
| Article | Year |
|---|---|
Puerarin alleviates the ototoxicity of gentamicin by inhibiting the mitochondria‑dependent apoptosis pathway.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line; Cell Survival; Gentamicins; Ha | 2021 |
RIPOR2-mediated autophagy dysfunction is critical for aminoglycoside-induced hearing loss.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Autophagy; Cell Adhesion Molecules; Gentamicins; He | 2022 |
Intratympanic Administration of Dieckol Prevents Ototoxic Hearing Loss.
Topics: Animals; Cisplatin; Furosemide; Gentamicins; Hearing Loss; Hyaluronic Acid; Rats | 2022 |
Cumulative risk factors contributing to hearing loss in preterm infants.
Topics: Case-Control Studies; Child; Deafness; Furosemide; Gentamicins; Hearing Loss; Humans; Infant; Infant | 2023 |
Enhanced mitochondrial membrane potential and ATP synthesis by photobiomodulation increases viability of the auditory cell line after gentamicin-induced intrinsic apoptosis.
Topics: Adenosine Triphosphate; Animals; Cell Line; Gentamicins; Hair Cells, Auditory; Hearing Loss; Low-Lev | 2019 |
Intratympanic gentamycine for Ménière's disease: is there a selective vestibulotoxic effect?
Topics: Anti-Bacterial Agents; Audiometry, Pure-Tone; Gentamicins; Hearing Loss; Humans; Meniere Disease; Tr | 2020 |
Artemisinin Loaded mPEG-PCL Nanoparticle Based Photosensitive Gelatin Methacrylate Hydrogels for the Treatment of Gentamicin Induced Hearing Loss.
Topics: Animals; Artemisinins; Drug Delivery Systems; Ethylene Glycols; Gelatin; Gentamicins; Guinea Pigs; H | 2020 |
Intratympanic gentamicin injection for refractory ménière's disease (MD) has potential effect in preventing contralateral MD occurrence.
Topics: Adult; Aged; Caloric Tests; Female; Gentamicins; Hearing Loss; Humans; Injection, Intratympanic; Mal | 2021 |
Effect of gentamicin and levels of ambient sound on hearing screening outcomes in the neonatal intensive care unit: A pilot study.
Topics: Aminoglycosides; Female; Gentamicins; Hearing Loss; Hearing Tests; Humans; Infant; Infant, Newborn; | 2017 |
Protective role of intratympanic nigella sativa oil against gentamicin induced hearing loss.
Topics: Animals; Cochlea; Disease Models, Animal; Evoked Potentials, Auditory, Brain Stem; Gentamicins; Guin | 2017 |
Targeted delivery of geranylgeranylacetone to mitochondria by triphenylphosphonium modified nanoparticles: a promising strategy to prevent aminoglycoside-induced hearing loss.
Topics: Cell Death; Cell Line, Tumor; Diterpenes; Drug Carriers; Gentamicins; Hair Cells, Auditory; Hearing | 2017 |
Brainstem auditory evoked responses in 37 dogs with otitis media before and after topical therapy.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Dogs; Ear, Middle; Evoked Potentials, Audit | 2018 |
Ferulic acid promotes survival and differentiation of neural stem cells to prevent gentamicin-induced neuronal hearing loss.
Topics: Animals; Animals, Newborn; Cell Differentiation; Cell Survival; Cells, Cultured; Cochlea; Coumaric A | 2017 |
SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides.
Topics: Aminoglycosides; Animals; Cell Death; Diterpenes; Drug Delivery Systems; Ear, Inner; Gentamicins; Ha | 2017 |
Novel SS-31 modified liposomes for improved protective efficacy of minocycline against drug-induced hearing loss.
Topics: Animals; Cell Survival; Disease Models, Animal; Gentamicins; Hair Cells, Auditory; Hearing Loss; Lip | 2018 |
[Small doses of gentamicin drum indoor injection treatment of intractableMénière disease clinical observation of the impact of the hearing].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Audiometry, Pure-Tone; Bone Conduction; Ear Ossicles; Fema | 2016 |
N-Methyl-D-Aspartate Receptors Involvement in the Gentamicin-Induced Hearing Loss and Pathological Changes of Ribbon Synapse in the Mouse Cochlear Inner Hair Cells.
Topics: Animals; Evoked Potentials, Auditory, Brain Stem; Female; Gentamicins; Hair Cells, Auditory, Inner; | 2018 |
Evaluation of Gentamicin Exposure in the Neonatal Intensive Care Unit and Hearing Function at Discharge.
Topics: Anti-Bacterial Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Gentamicins; Gestat | 2018 |
Clinical features and management of Meniere's disease patients with drop attacks.
Topics: Adult; Case-Control Studies; Endolymphatic Hydrops; Female; Gentamicins; Hearing; Hearing Loss; Hear | 2019 |
Pasireotide protects mammalian cochlear hair cells from gentamicin ototoxicity by activating the PI3K-Akt pathway.
Topics: Animals; Anti-Bacterial Agents; Female; Gentamicins; Hair Cells, Auditory; Hearing Loss; Hormones; H | 2019 |
Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cell Line; Drug Resistance, | 2019 |
Inflammation up-regulates cochlear expression of TRPV1 to potentiate drug-induced hearing loss.
Topics: Aminoglycosides; Animals; Calcium; Cell Survival; Cells, Cultured; Disease Models, Animal; Gene Expr | 2019 |
Cochlear inner hair cell ribbon synapse is the primary target of ototoxic aminoglycoside stimuli.
Topics: Aminoglycosides; Animals; Gentamicins; Hair Cells, Auditory, Inner; Hearing Loss; Immunohistochemist | 2013 |
Factors associated with permanent hearing impairment in infants treated with therapeutic hypothermia.
Topics: Brain Diseases; Female; Gentamicins; Hearing Loss; Humans; Hydrogen-Ion Concentration; Hypoglycemia; | 2013 |
Gentamicin administration on the stapes footplate causes greater hearing loss and vestibulotoxicity than round window administration in guinea pigs.
Topics: Animals; Anti-Bacterial Agents; Cochlea; Evoked Potentials, Auditory, Brain Stem; Female; Gentamicin | 2013 |
Red ginseng protects against gentamicin-induced balance dysfunction and hearing loss in rats through antiapoptotic functions of ginsenoside Rb1.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line; Cytochromes c; Down-Regulation | 2013 |
Risk of hearing loss in children exposed to gentamicin for the treatment of sepsis in young infancy: a community based cohort study in Pakistan.
Topics: Anti-Bacterial Agents; Female; Gentamicins; Hearing Loss; Humans; Infant; Male; Retrospective Studie | 2013 |
Middle ear gentamicin-soaked pledgets in the treatment of Ménière's disease.
Topics: Anti-Bacterial Agents; Drug Delivery Systems; Ear, Middle; Female; Gentamicins; Hearing Loss; Humans | 2014 |
Mitochondria-targeted antioxidant MitoQ reduces gentamicin-induced ototoxicity.
Topics: Animals; Antioxidants; Apoptosis; Cochlea; Cochlear Diseases; Evoked Potentials, Auditory, Brain Ste | 2014 |
Dynamic distribution of ototoxic gentamicin entry into inner hair cells of mice.
Topics: Alcohol Oxidoreductases; Animals; Anti-Bacterial Agents; Co-Repressor Proteins; Disease Models, Anim | 2014 |
Medication associated with hearing loss: 25 years of medical malpractice cases in the United States.
Topics: Adolescent; Adult; Child; Cisplatin; Databases, Factual; Female; Gentamicins; Hearing Loss; Humans; | 2014 |
Ototoxicity in Nigeria: why it persists.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimalarials; Audiometry; Child; | 2014 |
Role of somatostatin receptor-2 in gentamicin-induced auditory hair cell loss in the Mammalian inner ear.
Topics: Animals; Cell Death; Gene Expression Regulation; Gentamicins; Hair Cells, Auditory; Hearing Loss; Mi | 2014 |
Adjudin protects rodent cochlear hair cells against gentamicin ototoxicity via the SIRT3-ROS pathway.
Topics: Animals; Anti-Bacterial Agents; Cells, Cultured; Cochlea; Disease Models, Animal; Epithelium; Gentam | 2015 |
Circadian variation of gentamicin toxicity in rats.
Topics: Animals; Anti-Bacterial Agents; Circadian Rhythm; Drug Administration Schedule; Evoked Potentials, A | 2015 |
Effect of intratympanic application of efinaconazole 10 % solution in the guinea pig.
Topics: Animals; Antifungal Agents; Ear, Middle; Evoked Potentials, Auditory, Brain Stem; Gentamicins; Guine | 2016 |
Gentamicin extended interval regimen and ototoxicity in neonates.
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Female; Gentamicins; Hearing Loss; Humans; Inci | 2015 |
Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure.
Topics: Anti-Bacterial Agents; Cohort Studies; Female; Gentamicins; Hearing Loss; Hearing Tests; Humans; Inf | 2015 |
Auditory Function in Immature Animals after Two Consecutive Courses of Ototoxic Antibiotics.
Topics: Acoustic Stimulation; Animals; Anti-Bacterial Agents; Drug Administration Schedule; Evoked Potential | 2015 |
FGF22 protects hearing function from gentamycin ototoxicity by maintaining ribbon synapse number.
Topics: Acoustic Stimulation; Alcohol Oxidoreductases; Animals; Auditory Threshold; Co-Repressor Proteins; D | 2016 |
Prevention of gentamicin ototoxicity with N-acetylcysteine and vitamin A.
Topics: Acetylcysteine; Animals; Anti-Bacterial Agents; Free Radical Scavengers; Gentamicins; Hearing; Heari | 2016 |
[Protective effect of peperphentonamine injection through the otocyst against gentamicin- induced cochlear damage in guinea pigs].
Topics: 3,4-Methylenedioxyamphetamine; Animals; Apoptosis Regulatory Proteins; Beclin-1; Cochlea; Endothelin | 2016 |
Arctigenin protects against neuronal hearing loss by promoting neural stem cell survival and differentiation.
Topics: Animals; Cell Survival; Cells, Cultured; Cochlea; Evoked Potentials, Auditory; Furans; Gentamicins; | 2017 |
Therapeutic value of nerve growth factor in promoting neural stem cell survival and differentiation and protecting against neuronal hearing loss.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Cochle | 2017 |
Prevalence and independent risk factors for hearing impairment among very low birth weight infants.
Topics: Anti-Bacterial Agents; Craniofacial Abnormalities; Diuretics; Ductus Arteriosus, Patent; Evoked Pote | 2017 |
Spontaneous hair cell regeneration in the mouse utricle following gentamicin ototoxicity.
Topics: Animals; Anti-Bacterial Agents; Epithelial Cells; Gentamicins; Green Fluorescent Proteins; Hair Cell | 2009 |
Protective effect of melatonin against gentamicin ototoxicity.
Topics: Animals; Anti-Bacterial Agents; Cochlea; Drug Interactions; Gentamicins; Guinea Pigs; Hair Cells, Au | 2009 |
Aminoglycoside ototoxicity in Nicaraguan children: patient risk factors and mitochondrial DNA results.
Topics: Adolescent; Aminoglycosides; Child; Child, Preschool; Cross-Sectional Studies; DNA, Mitochondrial; D | 2009 |
Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.
Topics: Aminoglycosides; Animals; Bacteria; Cadherin Related Proteins; Cadherins; Cell Survival; Chlorocebus | 2009 |
Comparison of different aminoglycoside antibiotic treatments to refine ototoxicity studies in adult mice.
Topics: Amikacin; Aminoglycosides; Animals; Anti-Bacterial Agents; Cochlea; Disease Models, Animal; Dose-Res | 2010 |
A pattern of otoferlin expression interrupted by gentamicin exposure in ribbon synapse of inner hair cell in C57BL/6J mice.
Topics: Animals; Anti-Bacterial Agents; Auditory Threshold; Blotting, Western; Fluorescent Antibody Techniqu | 2009 |
High-dose intratympanic gentamicin instillations for treatment of Meniere's disease: long-term results.
Topics: Adult; Aged; Female; Follow-Up Studies; Gentamicins; Hearing Loss; Humans; Male; Meniere Disease; Mi | 2009 |
High systemic gentamicin levels and ototoxicity after implantation of gentamicin beads in a 70-year-old man--a case report.
Topics: Aged; Anti-Bacterial Agents; Arthritis, Infectious; Arthroplasty, Replacement, Hip; Drug Implants; G | 2009 |
Physiological dimensions of ototoxic responses in a model fish species.
Topics: Acoustic Stimulation; Acoustics; Animals; Audiometry; Auditory Threshold; Disease Models, Animal; Dr | 2010 |
Genetic mutations and aminoglycoside-induced ototoxicity in neonates.
Topics: Aminoglycosides; Female; Gentamicins; Hearing Loss; Humans; Infant, Newborn; Infant, Premature; Infa | 2010 |
Outcomes of endolymphatic shunt surgery for Ménière's disease: comparison with intratympanic gentamicin on vertigo control and hearing loss.
Topics: Adult; Aged; Anti-Bacterial Agents; Audiometry, Pure-Tone; Chi-Square Distribution; Ear, Inner; Endo | 2010 |
Can aspirin protect or at least attenuate gentamicin ototoxicity in humans?
Topics: Anti-Bacterial Agents; Aspirin; Female; Gentamicins; Hearing Loss; Humans; Male | 2010 |
A novel inner ear monitoring system for evaluating ototoxicity of gentamicin eardrops in guinea pigs.
Topics: Administration, Topical; Animals; Cochlea; Ear, Inner; Electromyography; Evoked Potentials, Auditory | 2010 |
Expression analysis suggests a potential cytoprotective role of Birc5 in the inner ear.
Topics: Animals; Cells, Cultured; Cytoprotection; Ear, Inner; Female; Gentamicins; Guinea Pigs; Hearing Loss | 2010 |
Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.
Topics: Animals; Cell Death; Disease Models, Animal; Evoked Potentials, Auditory, Brain Stem; Female; Gentam | 2010 |
[The self-protective effect of low dosage of gentamicin].
Topics: Animals; Cochlea; Evoked Potentials, Auditory, Brain Stem; Female; Gentamicins; Guinea Pigs; Hearing | 2009 |
Are gentamicin and/or vancomycin associated with ototoxicity in the neonate? A retrospective audit.
Topics: Anti-Bacterial Agents; Clinical Audit; Cochlear Implants; Dose-Response Relationship, Drug; Gentamic | 2011 |
Transient ischemia/hypoxia enhances gentamicin ototoxicity via caspase-dependent cell death pathway.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Blotting, Western; Caspases; Cell Line; Cochlea; Disease | 2011 |
Korean red ginseng prevents gentamicin-induced hearing loss in rats.
Topics: Animals; Anti-Bacterial Agents; Blotting, Western; Cell Survival; Gentamicins; Hair Cells, Auditory; | 2011 |
The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Antineoplastic Agents; Audiometry; Cisplat | 2011 |
Calreticulin binds to gentamicin and reduces drug-induced ototoxicity.
Topics: Animals; Anti-Bacterial Agents; Binding Sites; Calreticulin; Cell Survival; Fibroblasts; Gentamicins | 2011 |
Otoacoustic emission screen results in critically ill neonates who received gentamicin in the first week of life.
Topics: Anti-Bacterial Agents; Birth Weight; Critical Illness; Dose-Response Relationship, Drug; Drug Monito | 2011 |
Protective role of Nrf2 in age-related hearing loss and gentamicin ototoxicity.
Topics: Aging; Animals; Anti-Bacterial Agents; Ear, Inner; Gene Expression Regulation, Developmental; Gentam | 2011 |
Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses.
Topics: Animals; Anti-Bacterial Agents; Catalase; Dexamethasone; Gentamicins; Hearing Loss; Interleukin-1bet | 2012 |
Garlic-supplemented diet attenuates gentamicin-induced ototoxicity: an experimental study.
Topics: Animal Feed; Animals; Anti-Bacterial Agents; Audiometry; Auditory Threshold; Evoked Potentials, Audi | 2012 |
Mitochondrial ribosome and Ménière's disease: a pilot study.
Topics: Adult; Aged; DNA-Binding Proteins; Female; Genes, Mitochondrial; Genes, rRNA; Genetic Predisposition | 2012 |
Mitochondria-targeted antioxidant SkQR1 ameliorates gentamycin-induced renal failure and hearing loss.
Topics: Animals; Antioxidants; Gentamicins; Hearing Loss; Humans; Kidney; Male; Mitochondria; Organ of Corti | 2012 |
Effect of different gentamicin dose on the plasticity of the ribbon synapses in cochlear inner hair cells of C57BL/6J mice.
Topics: Animals; Disease Progression; Dose-Response Relationship, Drug; Gentamicins; Hair Cells, Auditory, I | 2012 |
Gentamicin affects connexin 26 expression in the cochlear lateral wall.
Topics: Animals; Cochlea; Connexin 26; Connexins; Disease Models, Animal; Gentamicins; Hearing Loss; Injecti | 2012 |
The effect of intratympanic methylprednisolone and gentamicin injection on Ménière's disease.
Topics: Anti-Bacterial Agents; Audiometry, Pure-Tone; Female; Gentamicins; Glucocorticoids; Hearing Loss; Hu | 2013 |
Distinction between innovative therapy and research.
Topics: Anti-Bacterial Agents; Connecticut; Gentamicins; Hearing Loss; Human Experimentation; Humans; Pharma | 2003 |
Protective effects of alpha-tocopherol against gentamicin-induced Oto-vestibulo toxicity: an experimental study.
Topics: alpha-Tocopherol; Animals; Auditory Threshold; Disease Models, Animal; Drug Interactions; Drug-Relat | 2003 |
Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo.
Topics: Abietanes; Animals; Anti-Bacterial Agents; Auditory Threshold; Cochlea; Drug Interactions; Drugs, Ch | 2003 |
Robust generation of new hair cells in the mature mammalian inner ear by adenoviral expression of Hath1.
Topics: Adenoviridae; Aging; Aminoglycosides; Animals; Animals, Newborn; Basic Helix-Loop-Helix Transcriptio | 2003 |
alpha-Tocopherol protective effects on gentamicin ototoxicity: an experimental study.
Topics: Action Potentials; alpha-Tocopherol; Analysis of Variance; Animals; Anti-Bacterial Agents; Antioxida | 2004 |
Vestibular destruction by slow infusion of gentamicin into semicircular canals.
Topics: Animals; Anti-Bacterial Agents; Chinchilla; Dose-Response Relationship, Drug; Gentamicins; Hair Cell | 2004 |
The role of antioxidants in protection from ototoxic drugs.
Topics: Action Potentials; alpha-Tocopherol; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antioxid | 2004 |
The status of the contralateral ear in established unilateral Menière's disease.
Topics: Adult; Anti-Bacterial Agents; Audiometry; Auditory Threshold; Female; Gentamicins; Hearing Loss; Hum | 2004 |
Flavanoid of Drynaria fortunei protects against gentamicin ototoxicity.
Topics: Animals; Anti-Bacterial Agents; Escherichia coli; Evoked Potentials, Auditory, Brain Stem; Flavones; | 2004 |
Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures.
Topics: Analysis of Variance; Animals; Animals, Newborn; Anti-Bacterial Agents; Apoptosis; Caspase 9; Caspas | 2004 |
Direct round window application of gentamicin with varying delivery vehicles: a comparison of ototoxicity.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Drug Delivery Systems; Fibrin; Gelatin Spon | 2004 |
Prevention of gentamicin induced ototoxicity by trimetazidine in animal model.
Topics: Animals; Anti-Bacterial Agents; Auditory Threshold; Cochlea; Epithelium; Evoked Potentials, Auditory | 2005 |
Argon protects hypoxia-, cisplatin- and gentamycin-exposed hair cells in the newborn rat's organ of Corti.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Antineoplastic Agents; Argon; Case-Control Studies | 2005 |
Efferent-mediated adaptation of the DPOAE as a predictor of aminoglycoside toxicity.
Topics: Adaptation, Physiological; Aminoglycosides; Animals; Anti-Bacterial Agents; Auditory Threshold; Dose | 2005 |
Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss.
Topics: Animals; Animals, Newborn; Apoptosis; Apoptosis Regulatory Proteins; Carnitine; Cell Line; Cochlea; | 2005 |
Unbiased quantification of Scarpa's ganglion neurons in aminoglycoside ototoxicity.
Topics: Adolescent; Adult; Aged; Cell Count; Female; Gentamicins; Hearing Loss; Humans; Male; Middle Aged; N | 2005 |
Outcomes in the use of intra-tympanic gentamicin in the treatment of Ménière's disease.
Topics: Anti-Bacterial Agents; Female; Gelatin Sponge, Absorbable; Gentamicins; Hearing Loss; Humans; Male; | 2006 |
Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy.
Topics: Adult; Audiometry; Female; Gentamicins; Hearing Loss; Humans; Male; Middle Aged; Retrospective Studi | 2006 |
Factors relating to the vertigo control and hearing changes following intratympanic gentamicin for intractable Ménière's disease.
Topics: Adult; Aged; Anti-Bacterial Agents; Audiometry, Evoked Response; Female; Gentamicins; Hearing Loss; | 2006 |
N-Acetylcysteine in the prevention of ototoxicity.
Topics: Acetylcysteine; Administration, Oral; Aminoglycosides; Anti-Bacterial Agents; Antioxidants; Bacterem | 2007 |
Aminoglycoside ototoxicity: How practical is this genetic screening test?
Topics: Aminoglycosides; Genetic Testing; Gentamicins; Hearing Loss; Humans; Mastoiditis; Sinus Thrombosis, | 2007 |
[Protective effect of adeno-associated virus-mediated neurotrophin-3 on the cochlea of guinea pigs with gentamicin-induced hearing loss].
Topics: Animals; Cochlea; Dependovirus; Genetic Therapy; Gentamicins; Guinea Pigs; Hearing Loss; Neurotrophi | 2007 |
[Therapeutic effect of insulin-like growth factor-1 injection into the inner ears through scala tympani fenestration on gentamicin-induced hearing loss in guinea pigs].
Topics: Animals; Ear, Inner; Gentamicins; Guinea Pigs; Hair Cells, Auditory; Hearing Loss; Insulin-Like Grow | 2008 |
Taurine attenuates aminoglycoside ototoxicity by inhibiting inducible nitric oxide synthase expression in the cochlea.
Topics: Aminoglycosides; Animals; Cochlea; Disease Models, Animal; Down-Regulation; Drug Interactions; Evoke | 2008 |
Gentamicin increases nitric oxide production and induces hearing loss in guinea pigs.
Topics: Animals; Cochlea; Evoked Potentials, Auditory, Brain Stem; Gentamicins; Guinea Pigs; Hearing Loss; M | 2008 |
Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis.
Topics: Adult; Auditory Threshold; Creatinine; Endocarditis, Bacterial; Female; Gentamicins; Hearing Loss; H | 1984 |
[Peri- and postnatal causes of juvenile hearing loss].
Topics: Bacterial Infections; Erythroblastosis, Fetal; Female; Fetal Hypoxia; Gentamicins; Hearing Loss; Hum | 1982 |
Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; | 1980 |
Netilmicin therapy of patients with septicaemia and other severe infections.
Topics: Adult; Aged; Creatinine; Dizziness; Drug Evaluation; Female; Gentamicins; Hearing Loss; Humans; Male | 1980 |
The use of pure-tone audiometry in the assessment of gentamicin auditory toxicity.
Topics: Audiometry; Audiometry, Pure-Tone; Auditory Threshold; Gentamicins; Hearing Loss; Humans | 1982 |
[Evaluation of hearing in patients treated with gentamicin].
Topics: Adult; Aged; Audiometry; Auditory Threshold; Bacteriuria; Gentamicins; Hearing Loss; Humans; Middle | 1980 |
Attenuation of gentamicin ototoxicity by glutathione in the guinea pig in vivo.
Topics: Animals; Auditory Threshold; Cochlea; Drug Interactions; Drug Resistance, Microbial; Ear, Inner; Evo | 1994 |
[Evaluation of hearing loss by means of inner ear acoustic emission in neonates treated with aminoglycoside].
Topics: Anti-Bacterial Agents; Gentamicins; Hearing Loss; Hearing Tests; Humans; Infant, Newborn; Infections | 1995 |
Are aminoglycoside antibiotics excitotoxic?
Topics: Animals; Anti-Bacterial Agents; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Fre | 1998 |
Low-dose intratympanic gentamicin treatment for dizziness in Ménière's disease.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Dizziness; Ear, Middle; Female; Follow- | 2000 |
Intratympanic gentamicin for the treatment of unilateral Meniere's disease.
Topics: Adult; Aged; Audiometry, Pure-Tone; Caloric Tests; Female; Gentamicins; Hearing Loss; Humans; Instil | 2000 |
Transtympanic versus sustained-release administration of gentamicin: kinetics, morphology, and function.
Topics: Animals; Anti-Bacterial Agents; Audiometry; Chinchilla; Delayed-Action Preparations; Ear, Middle; Fe | 2001 |
Hearing loss following intratympanic instillation of gentamicin for the treatment of unilateral Meniere's disease.
Topics: Adult; Aged; Anti-Bacterial Agents; Ear, Middle; Female; Gentamicins; Hearing Loss; Humans; Incidenc | 2002 |
Cystic fibrosis and hearing loss.
Topics: Acoustic Impedance Tests; Adolescent; Adult; Audiometry; Auditory Threshold; Child; Cystic Fibrosis; | 1979 |
[Effect of gentamicin on the organ of hearing in children].
Topics: Child; Child, Preschool; Gentamicins; Hearing; Hearing Loss; Hearing Loss, Bilateral; Humans | 1979 |
High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity.
Topics: Amikacin; Anti-Bacterial Agents; Audiometry; Gentamicins; Hearing Loss; Hearing Loss, Bilateral; Hea | 1992 |
Screening for aminoglycoside auditory toxicity in the old.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Audiometry; Bacterial Infections; Female; Gentamicin | 1990 |
[Clinical and experimental research on a kidney-tonifying prescription in preventing and treating children's hearing-loss induced by aminoglycoside antibiotic ototoxicity].
Topics: Adolescent; Animals; Anti-Bacterial Agents; Child; Child, Preschool; Drugs, Chinese Herbal; Evoked P | 1989 |